ENLV Enlivex Therapeutics

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
EN
01/10/2020

Underlying

ENLVEnlivex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enlivex Therapeutics

 PRESS RELEASE
Free
ENLV Enlivex Therape...

Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares

Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that Ondo Finance (“Ondo”) has launched ENLVon, the Ondo tokenized representation of ENLV’s ordinary shares on Ondo’s Global Markets platform. Through the launch of ENLVon, non-U.S. retail and institutional investors can gain direct economic exposure to Enlivex’s ordinary shares through digital infrastructure, without needing a traditiona...

April 8, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface ...

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt      According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers     The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction markets via the Rain decentralized platform through AI agents Nes-Ziona, Israel, ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 B...

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and business highlights for the year ended December 31, 2025. Net income for the year ended December 31, 2025 was $1.23 Billion and diluted earnings per ordinary share (EPS) was $25.48, driven by appreciation in the valuation of the Company’s treasury and t...

March 25, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction...

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program $21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investorThe Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22, 2026, for a total aggregate purchase amount of $10 millionThe Company and the Rain Foundation, which indepen...

March 24, 2026 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Quality Longevity Company Enlivex Receives Investigational New Drug (I...

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation model:  A clinical-stage quality longevity program powered by a prediction markets treasury strategy. IND clearance follows the positive 3 and 6-month data readout from the Company’s Phase 1/2a multicenter,...

March 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch